Skip to main content
Clinical Trials/NCT04092023
NCT04092023
Completed
Not Applicable

Effects of a Self-care Management Programme for Type 2 Adult Diabetic Patients With Poor Glycemic Control in General Out-patients Clinics - a Randomized Control Trial

Chinese University of Hong Kong1 site in 1 country200 target enrollmentOctober 2, 2018
ConditionsType 2 Diabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 Diabetes
Sponsor
Chinese University of Hong Kong
Enrollment
200
Locations
1
Primary Endpoint
Glycemic control
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Type 2 diabetes becomes the most prevalence chronic disease worldwide. Most type 2 diabetes patient are under the care in public general out-patient clinic in Hong Kong. The chronic nature of diabetic and the complexity of its management, on top of medication, diabetic patients often require behaviour modification and self-care management support. Effective diabetes self-care management education with patient-centered care approach with patients' participation and engagement has been shown to improve the clinical outcome. But such application during doctors' consultation are minimal in view of time limitation. Primary Care Nurse (PCN) is the first contact and is easily accessible in GOPCs. With support and training, PCN could act as a case manager to deliver the coordinated care. Interact and engage type 2 diabetes patients in self-care management, and work with multidisciplinary team in providing patient-centered care in GOPC setting. As there is lack of evidence about adopting such approach in the investigator's local population. This study is to test the effectiveness of the PCN led self-care management program to improve patients' clinical outcomes.

Detailed Description

1. Safety Assessment There is no harmful effect from the intervention. 2. Statistics (A) Sample Size Estimation With reference from previous study (Aanand et al. 2011), the sample size is calculated by assuming change the reduction of HbA1c is 0.59% (intervention group 8.05% (SD 1.40) versus control group 8.64% (SD 1.39). In order to have 80% power and 5% false positive error, a sample size of 88 is needed for each arm using the public domain sample size calculator (https://www2.ccrb.cuhk.edu.hk/stat/). After consideration of 10% attrition rate, 97 participants will be recruited in each arm. (B) Data Analysis All statistical analyses will be performed using SPSS Windows 22.0 program. P-value less than 0.05 will be considered statistically significant. All treatment evaluations will be performed on the principle of intention-to-treat analysis of the difference in outcomes between groups at 6 months after baseline. Missing values will be imputed using last value carrying forward method. Repeated analysis will be done for per-protocol analysis. Demographics and baseline characteristics will be summarized using descriptive statistics. Continuous variable will be summarized as numbers of observed values, mean and standard deviation. Categorical variables will be described as frequency and percentage. Information collected on all outcomes will be first summarized using descriptive statistics at baseline and at 6 months as appropriate. Linear regression model will be used to test the effect of intervention on the outcomes between 2 groups. 3. Direct Access to Source Data and Documents Apart from the outpatient number and Initials, no subject sensitive identifier will be contained in the completed questionnaires. All completed questionnaires will be kept in knocked administrative room in research site with limited access by investigators. All patient records in CMS will be accessed by investigators only by their own CMS login. 4. Quality Control and Quality Assurance Expert panel including family medicine specialist, diabetes nurse consultant, diabetes nurse working in primary health care setting, dietitian, physiotherapist and podiatry will review the education contents. Nurses who have received structural education on chronic disease management as organized by Institute of Advanced Nursing Studies, Hospital Authority will be assigned to provide intervention to participants. All the interventionist and co-investigator will be trained for 4 hours by principal investigator for the objectives, contents and process of program before implementation. Meeting will be held during the process of data collection to exchange ideas and knowledge between the interventionist. Principal investigator will monitor in all study phase. The interaction between interventionists and participants will be guided by protocol and guideline. Co-investigator in individual clinic will monitor participants' recruitment and data collection. Principal investigator will randomly check and sit in to monitor the consistency. 5. Ethics and Data Handling Ethics of this study will be complied with the Declaration of Helsinki. Investigators will explain the study in detail and subjects will sign an informed consent form with written information sheet. Investigators will clarify all the queries with subjects. The enrolment will be entirely voluntary and it will not affect their care received in the study site. All the personal identifiers will be removed during data processing. The relevant documents will be kept in a locked cabinet in the study site and will be retained for 3 years after the study end.

Registry
clinicaltrials.gov
Start Date
October 2, 2018
End Date
September 1, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Chan Ching Yee

Principal Investigator

Chinese University of Hong Kong

Eligibility Criteria

Inclusion Criteria

  • Clinically diagnosed of type 2 diabetes
  • Poorly glycemic control with recent HbA1c ≧ 7.5%
  • Chinese participants who could speak Cantonese

Exclusion Criteria

  • Unable to perform self-care management due to physical or mental limitation
  • Engage in another similar program
  • Life expectancy \<1 year due to malignancies or other terminal illness

Outcomes

Primary Outcomes

Glycemic control

Time Frame: Assess change from Baseline HbA1c at 6 months

Blood test for HbA1c

Secondary Outcomes

  • QOL: Audit of Diabetes Dependent Quality of Life (ADDQoL-19)(Assess change from Baseline HbA1c at 6 months)
  • Self-Efficacy: Diabetes Empowerment Scale - Short Form (C-DES-SF)(Assess change from Baseline HbA1c at 6 months)
  • Diabetes Knowledge(Assess change from Baseline HbA1c at 6 months)

Study Sites (1)

Loading locations...

Similar Trials